Patients older than 60 years of age or with a history of thrombosis are considered at high risk for thrombosis, and platelet activation is enhanced and the risk of thrombus formation is increased, especially in patients with ET with JAK 2 mutations [2, 3]. The gene discussed is JAK2; the disease is Venous thrombosis.